Pharmacotherapy of chronic pulmonary arterial hypertension: value and limitations. Part II: Secondary pulmonary hypertension.
Part I of this review discussed pharmacotherapy of primary pulmonary hypertension (PHT). Part II describes the value and limitations of oxygen and vasodilator therapy of secondary PHT, focusing on patients with PHT associated with selected connective tissue disease and chronic nonthrombotic hypoxic lung disease.
Alpert
M A
MA
Division of Cardiology, University of South Alabama, College of Medicine, Mobile.
Concannon
M D
MD
Mukerji
B
B
Mukerji
V
V
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002908:Chronic Disease; D003240:Connective Tissue Diseases / Q000150:complications; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy*; D010100:Oxygen / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D010100:Oxygen